A recent comprehensive study has cast doubt on the widely held belief in the benefits of medical cannabis, revealing significant risks that may outweigh its advantages. The research, led by Dr. Michael Hsu, an addiction psychiatrist at UCLA, found “insufficient evidence” to support many of the purported therapeutic effects of cannabis. As more Americans turn to marijuana for relief from chronic pain, anxiety, and other health issues, these findings prompt a reevaluation of its safety and efficacy.
The study analyzed over 2,500 scientific papers published from January 2010 to September 2025, focusing on the effectiveness of medical cannabis compared to FDA-approved medications containing cannabinoids such as THC and CBD. While pharmaceutical-grade products showed clear benefits for conditions like chemotherapy-induced nausea and certain severe pediatric seizure disorders, the report indicates that the expected therapeutic outcomes from medical cannabis are not as robust as public perception suggests.
Dr. Hsu emphasized the necessity for transparent discussions between healthcare providers and patients regarding the limitations of cannabis. “Patients deserve honest conversations about what the science does and doesn’t tell us about medical cannabis,” he stated.
The findings reveal that although over half of medical cannabis users seek it for acute pain relief, there is no solid clinical evidence supporting its effectiveness for this purpose. Current medical guidelines do not recommend cannabis as a first-line treatment for pain management. Furthermore, the study identified weak or inconclusive research regarding cannabis’s impact on conditions such as insomnia, anxiety, and PTSD.
Hidden Risks Associated with Medical Cannabis
The researchers noted alarming potential dangers linked to cannabis use, particularly among adolescents. Studies suggest that those using high-potency cannabis are at a greater risk of developing psychotic symptoms, with 12.4% affected compared to 7.1% of users opting for lower-potency products. Additionally, 19.1% of adolescents using potent cannabis experienced generalized anxiety disorder, compared to 11.6% of their peers using less potent forms.
Moreover, approximately 29% of medical cannabis users meet the criteria for cannabis use disorder—a complex psychiatric condition characterized by a compulsive urge to use cannabis, increased tolerance, and withdrawal symptoms. The risk of developing this disorder is notably higher for individuals who begin using cannabis before the age of 18, who are four to seven times more likely to develop dependence compared to adults.
Long-term use of medical cannabis, especially high-potency or inhaled products, has also been linked to increased cardiovascular risks, including a higher likelihood of heart attack, stroke, and coronary artery disease. In light of these findings, Dr. Hsu and his team recommend that medical professionals screen patients for cardiovascular disease and mental health disorders before considering prescribing THC-containing products. They urged doctors to carefully evaluate potential drug interactions and weigh the benefits against the risks.
Call for Further Research and Regulatory Changes
While the study provides crucial insights, the researchers acknowledged several limitations, including that it was not a systematic review and did not include a formal assessment of bias. They highlighted the variability in study designs, cannabis products tested, and participant characteristics, which may influence the applicability of the findings to individual patients.
“Further research is crucial to better understand the potential benefits and risks of medical cannabis,” Dr. Hsu stated. He emphasized that supporting more rigorous studies could lead to clearer guidance for clinicians and improve patient care.
These findings come at a time when speculation is growing regarding potential changes in cannabis regulation. Reports suggest that President Trump may soon consider reclassifying cannabis under federal law, potentially moving it from a Schedule I drug—where it is categorized alongside substances like heroin—to a lower classification that acknowledges its medical uses. This shift could significantly impact the cannabis market, with stocks surging in anticipation of regulatory changes.
As discussions around medical cannabis continue, the need for informed, evidence-based decisions remains paramount for healthcare providers and patients alike.
